Noncash interest expense on deferred royalty obligations
41,345
39,873
38,678
86,460
Change in fair value of the embedded derivative associated with the deferred royalty obligation
3,572
2,158
8,590
11,062
Amortization of debt discount and issuance costs
1,926
1,819
1,452
4,515
Noncash income from equity method investments
-
-
1,064
7,769
Depreciation and amortization
1,053
1,186
1,435
3,999
Gain on deconsolidation of subsidiaries
-
-
-
0
(gain) loss on deconsolidation of subsidiaries
-
-
0
-
Noncash lease expense
1,628
1,466
1,459
3,443
Gain from investment in equity securities, net
-
-
0
0
Loss on extinguishment of debt
0
0
0
-21,155
Accrual of payment-in-kind interest on term loan
-
-
0
-
Dividend from investment in equity securities
0
-
-
-
Other noncash adjustments, net
-1,196
-306
434
1,217
Accounts receivable, net
49,258
65,782
22,926
111,796
Inventories
21,113
7,053
1,951
23,356
Prepaid expenses and other current assets
1,382
18,845
-8,750
17,527
Other assets
1,488
1,795
-545
-568
Accounts payable
-1,856
-7,170
17,525
9,084
Accrued compensation and benefits
11,721
-37,476
19,810
3,212
Accrued research and development liabilities
10,038
12,994
6,816
347
Operating lease liabilities
-1,822
-1,852
-1,790
-4,757
Deferred revenue
-1,921
-2,379
-1,948
-9,480
Other liabilities
47,788
4,617
24,780
53,030
Net cash used in operating activities
-71,101
-197,279
-56,420
-389,490
Purchases of marketable securities
11,271
52,666
17,321
10,876
Maturities of marketable securities
29,600
10,000
3,000
8,000
Purchases of investments in equity securities
-
-
0
0
Proceeds from sales of investments in equity securities
-
-
0
0
Proceeds from special cash dividends received from an investment in equity securities
-
-
0
2,302
Payment for intangible assets
0
0
0
8,495
Purchases of property and equipment
443
69
33
1,064
Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries
-
-
0
0
Net cash used in investing activities
17,886
-42,735
-14,354
-10,133
Proceeds from issuance of 2033 notes /2031 notes-A2033Convertible Senior Notes
0
632,500
-
-
Issuance costs and discounts associated with 2033 notes/2031 notes-A2033Convertible Senior Notes
431
12,796
-
-
Proceeds from issuance of 2033 notes /2031 notes-A2031Convertible Senior Notes
0
0
0
575,000
Proceeds from royalty obligation-Royalty Interest Purchase And Sale Agreement
-
-
300,000
-
Issuance costs and discounts associated with 2033 notes/2031 notes-A2031Convertible Senior Notes
0
0
0
12,034
Issuance costs and discounts associated with a royalty obligation-Royalty Interest Purchase And Sale Agreement
-
-
3,010
-
Proceeds from a royalty obligation under the royalty purchase agreement
-
-
-
300,000
Proceeds from royalty obligation under royalty purchase agreement (as described in note 9)
0
-
-
-
Proceeds from royalty obligation-Funding Agreement
-
-
0
-
Issuance costs associated with royalty obligation under royalty purchase agreement
-3,010
-
-
3,010
Issuance costs and discounts associated with a royalty obligation-Funding Agreement
-
-
0
-
Proceeds from term loan under the amended financing agreement-Financing Agreement
-
-
0
0
Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-Financing Agreement
-
-
0
0
Repayment of term loans
0
0
0
459,000
Repayments of deferred royalty obligations
21,789
11,293
8,564
6,896
Repurchase of common stock
127,503
82,500
0
48,276
Repurchase of rsu shares to satisfy tax withholding
4,267
4,074
7,430
6,796
Proceeds from issuance of common stock through public offerings, net
-
-
0
0
Proceeds from stock option exercises, net of repurchases
5,223
22,589
13,212
14,523
Proceeds from common stock issuances under espp
0
5,466
0
6,414
Transactions with noncontrolling interests
0
0
600
1,550
Net cash provided by financing activities
-148,767
549,892
-2,182
361,475
Net increase in cash, cash equivalents, and restricted cash
-201,982
309,878
-72,956
-38,148
Cash, cash equivalents, and restricted cash at beginning of period
882,018
572,140
645,096
683,244
Cash, cash equivalents, and restricted cash at end of period
680,036
882,018
572,140
645,096
Noncash interest expense on deferred royalty obligations
10,936
-
-
-
Repayments of deferred royalty obligations
5,784
-
-
-
Transfers to noncontrolling interests
-5,464
-
-
-
Recognized intangible asset recorded to other current liabilities
0
-
-
-
Deferred and unpaid issuance costs recorded to other current liabilities
1,355
-
-
-
Cash and cash equivalents
677,911
-
-
-
Restricted cash included in prepaid expenses and other current assets
549
-
-
-
Restricted cash included in other assets
1,576
-
-
-
Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows
680,036
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.